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In this study, an in vitro model of immune complex-
mediated basement membrane zone separation cau sed 
by periphigoid antibodies, serum complement, and pe-
ripheral blood leukocytes is described. When cryostat 
sections of fresh-frozen normal human skin were treated 
with either of 4 bullous pemiphigoid sera containing 
cOJDplement-activating anti-basement membrane zone 
antibodies and subsequently incubated at 37 °C with nor-
mal human peripheral blood leukocytes and fresh human 
serum, leukocytes attached to 96% of the basement mem-
brane zone in 100% of sections. Sixty-seven percent of 
the sections developed focal areas of basement mem-
brane zone separation resembling dermal-epidermal 
separation described in early pemphigoid lesions. In con-
trol sections in which either leukocytes, pemphigoid an-
tibody or fresh human serum were omitted, significantly 
less leukocyte attachment and basement membrane zone 
separation occurred. Evidence that leukocytes caused 
separation was supported by an absolute requirement 
for viable leukocytes during incubation, a high correla-
tion between leukocyte attachment and separation and 
experiments showing that leukocytes attached to the 
basement membrane zone were activated. This study 
provides the first in vitro evidence directly supporting a 
functional role for immune-complex mediated inflam-
mation in the pathogenesis of basement membrane zone 
separation and blisters in bullous pemphigoid. 
Bullous pemphigoid (BP) is an acquired chronic inflamma-
tory blistering disease of skin and mucous membranes [1]. It is 
associated with linear deposits of immunoglobulin G (IgG) and 
complement (C) at the cutaneous basement membrane zone 
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(BMZ) and anti-BMZ antibodies (pemphigoid antibodies) in 
sera. Histologic and ultrastructural studies have shown that 
blisters result from dermal-epidermal separation which occurs 
subsequent to infiltration of leukocytes into the upper dermis 
and injury to cellular and structural components of the BMZ. 
Cellular inflammation, tissue injury, and dermal-epidermal 
separation in BP may be initiated by immune complexes com-
posed of anti-BMZ antibodies and an antigen (BP antigen) in 
the lamina lucida [2,3]. It has been suggested that complexes 
activate C and that C-derived mediators recruit and activate 
leukocytes which subsequently release proteases that cause 
tissue injW'y. Although the proposal is consistent with many of 
the histologic, ultrastructural, and immunologic features of the 
disease and with the known functional interactions between 
leukocytes, C and immune complexes in vitro, there has been 
no model to test the hypothesis and no direct evidence sup-
porting a functional role for immune complexes in BMZ injury. 
Previous attempts to induce skin injury or inflammation by 
passive transfer of pemphigoid antibody or pemphigoid anti-
body and C in animals or organ cultures of skin have been 
uniformly unsuccessful [4-6]. 
Recently, we reported an in vitro method in which a func-
tional interaction between skin, anti-BMZ antibodies, leuko-
cytes, and C was demonstrated [7,8]. In those studies it was 
shown that normal human peripheral blood leukocytes (PBL) 
would attach to the BMZ of cryostat sections of normal human 
skin treated with BP sera (BPS) containing C-binding anti-
BMZ antibodies. The attachment of leukocytes to the BMZ 
was shown to require serum C and involved C-mediated di-
rected migration of cells to the BMZ. In this study the method 
has been modified and used to demonstrate that leukocytes, 
recruited and· adherent to the BMZ, are activated and cause 
BMZ damage in vitro histologically similar to that observed in 
lesions [9). 
MATERIALS AND METHODS 
$Ilin 
Fresh-frozen normal human foreskins from 12 neonates was used as 
a source of skin. Skin was obtained within minutes of routine circum-
cision, frozen at -70°C, embedded in Ames OCT Compound (Ames Co. 
Elkhart, IL) and stored at -70°C un til used. Skin not used within four 
weeks was discarded. 
Sera. 
Foul' BPS (BPS 1-4) and 4 normaI human control sera (NHS 1-4) 
were collected from volunteers and stored in l.0 ml aliquots at -70°C. 
Prior to use, sera were heat- inactivated (BPSi, NHSi) at 56°C for 30 
min and dilu ted 1:10 in 0.15 M NaCI buffered with 0.01 M Na2HPO., and 
NaI-hPO., pH 7.2 (PBS) . All BPS were obtained from patients with 
active BP diagnosed by established clinicaI, histologic and immuno-
histologic criteria [1]. Only BPS conta ining C3-binding ant i-BMZ ant i-
bodies at t iters > 1:10 were used. IgG and C3-binding an t i-BMZ 
antibody titers were determined using an established immunofluores-
cent method [10]. The t iters are listed in Table I. 
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T ABLE 1. A nti-BMZ antibody titers in B PS 1-4 
TITERS 
BPS IgG Anti-BMZ C3 Binding 
An tibody Anti-BMZ Antibody 
1 1:1280 1:320 
2 1:1280 1:640 
3 1:1280 1:160 
4 1:1280 1:320 
TABLE II. Protocol for treatments A-E 
Treat- Description Step 1 
ment Step 2 Step 3 SE
I
, 
A Experimental BPSi PBL WHS 74 
B Leukocyte Control BPSi Buffer WHS 57 
C Viable Leukocyte Control BPSi Killed" WHS 59 
PBL 
D Complement Control BPSi PBL WHSi 65 
E Anti-BMZ Antibody Con- NHS i PBL WHS 63 
trol 
" PBL were killed in the chambers by freeze-thawing chambers at 
-70°C 30 min after incubation of chambers at 37°C. Following freeze-
thaw, incubation at 37°C was continued. 
" SE = number of skin sections examined. 
Complement 
Fresh-frozen platelet-poor whole human serum (WHS) from a single 
blood group AB, type Rh positive donor was used as a source of serum 
C in all studies. Blood was collected under s terile condi tions and 
platelet-poor WHS prepared as previously described [7]. 1.0 ml aliquots 
of WHS were stored frozen at -70°C. Some aliquots were heat-inacti-
vated (56°C x 30 min) for use as a C control , (WHSi) . 
Peripheral Blood- L eukocytes 
PBL from normal human donors were prepared by dextran sedimen-
tation of heparinized whole blood as previously described [7]. Following 
dextran sedimentation for 30 min at 37°C, the leukocyte-rich supernate 
was recovered and cells washed twice in 10.0 ml Geys balanced salt 
solu t ion (Flow Labs, McLean, V A) conta ining 2% bovine serum albumin 
(GBSS). T otal leukocyte coun ts and percentage of granulocytic cells 
were determined by counting methylene-blue stained cells in a hemo-
cytometer. The percentage of granulocytes was consistently 70-85%. 
Cell viability determined by trypan blue exclusion was always 98% or 
greater. 
Trea"tment of Skin Sections Using a 3-Step Skin Chamber M ethod 
S tep I-Treatment of skin with BPS: Two freshly cut 8-um sections 
of skin measuring 1-1.5 X 0.3 - 0.5 cm were placed in the center of 
gelatin-coated microscope slides (t issue slides), a llowed to dry for 3-5 
min at 25°C and treated identically as follows: Each section was 
overlaid with 50 ul of a 1:10 dilution of heat-inactivated BPS (BPSi) or 
NHS (NHSi) as control and incubated for 30 min at 4°C in a humidi ty 
chamber. Slides were then rinsed for 15 min in 3 changes of cold (4 °C) 
PBS. 
Step 2-Treatment of sections with PBL: Following the fmal rinse, 
excess moisture was blotted away and sections incubated at 37°C for 10 
min with either 100 ul/section of 10 x 10" PBL in GBSS or buffer alone. 
Following incubation, sections were gently immersed in PBS for 5 min 
at 25°C to remove nonadherent cells. Following the rinse to remove 
nonadherent cells, excess moisture was blotted from the slides and 
chambers prepared as previously described [7,11]' Briefl y, chambers 
were prepared by covering t issue slides wi.th a second microscope slide 
to which 2 thicknesses of #88 vinyl electrical tape (3M CO, St. Paul, 
MN) had been attached at each end. The tape prevented contact 
between the covering slide and skin sections and created a chamber 
approximately 0.2 mm thick with a volume of 0.4 m!. The ends of the 
slides were then secured with Highland 6200 cellophone tape (3M Co.) . 
Step 3-Addition of WHS and incubation of chambers: Immedi-
ately after chambers were assembled, 0.4 ml of 5% WHS or WHSi 
dilu ted in GBSS was injected in to the chambers using a 1.0 ml tuber-
culin syringe and 27 gauge needle. Special care was taken to completely 
fill the chambers, cover tissue sections with serum and avoid air 
bubbles. Chambers were then placed in a humidified a ir incubator at 
37°C for 60, 90 or 120 min. Following incubation, chambers were 
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immediately disassembled and excess serum and nonadherent cells 
removed by gently immersing slides in cold PBS for 10 min. S lides were 
then air-dried at 25°C for 10 min, fixed in 95% ethanol, stained with 
hema toxylin and eosin (H&E ) a nd permanen tly moun ted with covel"-
slips. 
Exp erimenta l protocol. The following protocol was used for each 
experiment (Table II) . Triplicate chambers were prepared fo r each of 
5 t reatments (A-E) . Skin sections in treatment A rece ived 1 of 4 BP Si 
in Step I , PBL in S tep 2 and 5% WHS in S tep 3. In treat ment B 
(leukocyte control) PBL were omit ted in S tep 2. Sections in treatment 
C (viable leukocyte control) were treated the same as A but PBL were 
killed in the chamber by freeze-thawing the chamber X 1 at -70°C, 30 
min after incubation at 37°C. Following freeze-thaw, incubation at 37°C 
was resumed. Sections in t reatment D (complement cont rol) received 
5% WHSi instead of 5% WHS. Sections in trea tment E (negative 
control) received 1 of 4 NHS i in place of BPSi. All 15 chambers in each 
experiment (3 chambers for each of trea tments A-E) were prepared 
using skin sections cut from the same t issue, the same BPS i or NHSi 
and PBL from the same donor. One chamber from each treatment was 
then incubated for 60, 90, or 120 min. E xperiments including all 5 
treatments were performed for each of the 4 BPS in triplicate. 
Evaluation of leukocyte attachment and BMZ separation . H&E-
stained sections were examined for leukocyte attachment and BMZ 
separation at 250x using a light microscope equipped with a lOx filar 
linear micrometer eyepiece (American Optical Corp, Buffalo, NY). 
Leukocyte attachment to the BMZ was determined in all sections 
t reated with PBL by examining for a side-by-side, nom andom, linear 
attachment of cells to the BMZ as shown in Fig 1. A percent of total 
BMZ with attached leukocytes was then calculated as follows: (length 
of BMZ wi th attached cells/total length of BMZ) x 100% = percen t 
at tachment. In this study, BMZ separation was defined as ar eas of 
apparent dermal-epiderma l separation in which continuity between 
dermis and epidermis was lost (Fig 2). The length of these areas was 
measured and a percent of total BMZ separation was determined for 
each section as follows: (length ofBMZ separated/total length ofBM Z) 
x 100% =: percent separation. BMZ separation was also expressed as a 
ratio or percent of sections with separation of total sections treated. 
A ctivation of PBL at the BMZ. To de termine if PBL attached to 
the BMZ were ac tivated, expcriments were pcrformed as follows. 
Duplicate skin sections were treated with each of 4 BPS as outlined 
above for treatment A. Chambers were assembled and injected with 5% 
WHS containing 0.05% nit roblue tetrazolium (NBT) obtained from 
Sigma Chemical Co, St. Louis, MO. 'Chambers were then incubated for 
30 min at 37°C, disassembled and sections rinsed for 10 min in PBS. 
Unfixed tissue preparations were exa mined by light microscopy at 
400x. Leukocyte activation was assessed by examining attached cells 
for evidence of intracellular precipitates of blue formazan (reduced 
NBT) [12]. Controls were performed using skin sections t reated with 
NHSi in place of BPSi. 
Analysis of Data. Statistical analysis of results was performed using 
both parametric and nonpammetric tests including analysis of variance, 
.. 
I a 
FIG 1. Example of leukocyte attachment to the BMZ of skin sections 
incubated with bullous pemphigoid serum, peripheral blood leukocytes, 
and whole human serum. Note the linear, side-by-side, nom andom 
distribu t ion of leukocytes along the BMZ (arrows) (reduced from x 
125). 
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linear analysis of categorical data, Friedmans analysis of nonparametric 
data and correlation analysis. 
RESULTS 
Recovery of Shin Sections for Analysis of Leulwcyte 
Attachment and BMZ Separation 
In this study 3 elements affecting leukocyte attachment and 
the induction of BMZ separation were examined: (1) type of 
treatment (A-E); (2) BPS (BPS 1-4); and (3) time of incubation 
(60, 90 and 120 min) at 37°C. A total of 366 skin sections were 
treated in 60 combinations of treatment, BPS and incubation 
time according to the protocol shown in Table II. Of the 366 
sections, 318 (87%) were recovered for examination of attach-
ment and damage. The number of sections available for exam-
ination (SE) in treatments A-E is shown in Table II. The 
remaining sections (13%) were either lost (washed off slides) 
during the procedW"e or insufficiently preserved for examina-
FIG 2. An example of basement membrane zone damage in skin 
sections treated with bullous pemphigoid serum, peripheral blood leu-
kocytes and whole human serum. Note the clea.r space (V) resembling 
a micro-vesicle between epidermis (E) and dermis (D) . Several leuko-
cytes are present in the clear space and along the basement membrane 
zone adjacent to the space (reduced from x 400). 
TABLE Ill. Effect of treatment on induction of BMZ separation and 
leuhocyte attachment 
Treatment BMZ separation Attachment 
SS/SE" (%) PS" (% ± SD)C PA" (% ± SD) 
A (67) 6.1 ± 2.2 96.5 ± 2.5 
B (0) 0 
C (0) 0 0 
D (18.5) 1.4 ± 0.6 18.1 ± 25.4 
E (5.0) 0.1 ± 0.2 0.5 ± 0.7 
" SS/SE = Sections showing separation/ sections examined. 
b PS = Percent of BMZ separation . 
C SD = standard eviation. 
d P A = Percent attachment. 
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tion. To determine if recovery of sections was influenced by 
treatment, BPS or incubation time, the percent of sections 
recovered to total sections treated in each combination of 
treatment, BPS and incubation time was calculated. There was 
a 100% recovery of sections in 32 combinations, 83% in 11; 67% 
in 15 and 33% in 2. Analysis showed no significant differences 
in recovery of skin sections due to treatment, BPS or incubation 
time. 
Effect of Treatment on Induction of BMZ Separation 
The effect of treatments A-E on induction ofBMZ separation 
was assessed in all 318 recovered skin sections independent of 
BPS or incubation time. The results are summarized in Table 
III. In treatment A, 50 sections (67%) showed areas of BMZ 
separation varying in length from 20 - > 1000 um. The percent 
oftotal BMZ separation was 6.1%. In treatments Band e, there 
was no evidence of BMZ separation in any of the sections. In 
treatment D , 12 sections (18%) showed BMZ separation and 
the percent of total BMZ separation was 1.4%. In treatment E , 
only 3 sections (5%) showed BMZ separation and the percent 
of BMZ separation was 0.1%. An analysis of variance of these 
results showed there was both a significantly greater percent of 
sections with separation and percent of total BMZ separation 
in treatment A compared to treatments B, e, D, and E (p < 
.001 andp < .01 respectively). Furthermore, there was a greater 
percent of sections with separation (p < .01) and percent of 
BMZ separation (p < .01) in treatment D than in treatments B, 
e, and E. 
Effect of Treatment on Leulwcyte Attachment 
The effect of treatment on leukocyte attachment was deter-
mined in all 318 sections independent of BPS or incubation 
time. A mean percent of total BMZ with attached leukocytes, 
percent attachment, was calculated for all sections in each 
treatment except B which received no PBL. The results (Table 
III) show the percent attachment in treatments A, C, D , and E 
were 96.4%, 0,18.1% and 0.5% respectively. Percent attachment 
in treatment A was significantly greater (p < .001) than in 
treatments C, D, and E. In addition, percent attachment in 
treatment D was greater (p < .01) than in treatments e or E. 
Effect of BPS on Induction of BMZ Separation in 
Treatments A and D (Table 1'1. 
Since significant BMZ separation was observed only in treat-
ments A and D, these treatments were analyzed to determine 
if there was any difference between BPS in inducing separation. 
In treatment A, there were 18 sections treated with BPS #1, 16 
with BPS #2, 24 with BPS #3 and 16 with BPS #4. The 
percent of sections in treatment A showing BMZ separation for 
BPS #1 was 67%, for BPS #2, 69%; for BPS #3, 75% and for 
BPS #4, 56%. The percent of total BMZ separation for the 4 , 
BPS was: BPS #1,8.7%; BPS #2, 6.0%; BPS #3, 6.5% and BPS 
#4, 3.3%. An analysis of variance for percent of sections sepa-
ration and percent of total BMZ separation in treatment A 
showed no significant differences between the 4 BPS. Similar 
results were observed in treatment D where no significant 
TABLE IV. Effect of BPS on induction of BMZ separation a.nd leul/.Ocyte a.ttachm.ent in treatments A and D 
Treatment A 
BPS 
BMZ separution 
1 
2 
3 
4 
SS/ SE (%)" 
67 
69 
75 
56 
PS" (%±SD)c 
8.7 ± 2.6 
6.0 ± 2.6 
6.5 ± 2.6 
3.3 ± 2.0 
" SS/SE = Sections separated/sections examined. 
b PS = Percent of BMZ sepa.ration. 
C SD = standa.rd deviation. 
d P A = Percentage attachment. 
Attachment 
PA (%±SD)" 
99.1 ± 0.9 
96.5 ± 3.2 
93.0 ± 7.0 
97.2 ± 2.5 
Treatment D 
BMZ separation 
SS/ SE (%) 
13 
]3 
22 
23 
PS (%±SD) 
0.6 ± 0.7 
1.7 ± 1.6 
1.9 ± 2.3 
1.3 ± 1.2 
Attachment 
PA (%±SD) 
56.3 ± 9.1 
1.0 ± 0.5 
6.5 ± 3.1 
9.0 ± 6.4 
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TABLE V. Effect of incubation time on induction of BMZ separation and leu/wcyte attachment in treatments A and D 
Treatment A Treatment 0 Incubation 
time (min) BMZ separation Attachment BMZ separation Attachment 
60 
90 
120 
SS/SE (%)" PS" (%±SD)," 
62 4.1 ± 1.6 
80 7.8 ± 1.9 
62 6.4 ± 3.9 
PA" (%±SD) 
94.6 ± 6.9 
98.7 ± 1.0 
96.0 ± 2.0 
SS/ SE (%) 
19 
32 
4 
PS (%±SD) 
1.5 ± 0.3 
1.9 ± 1.2 
0.7 ± 1.3 
PA (%±SD) 
23.1 ± 28.6 
19.3 ± 23.7 
11.9 ± 18.5 
" SS/SE = Sections separated/sections examined. 
" 1'S = Percent of BMZ separation. 
" SD = standard deviation, 
"PA = Percent attachment. 
difference in BMZ separation due to BPS was observed (Table 
IV). 
Effect of BPS on Leukocyte Attachment in Treatments A and 
D 
To determine if BPS had a significant effect on leukocyte 
attachment in treatments A and D, percent attachment was 
calculated in both treatments for each of the 4 BPS. The results 
(Table IV) showed that in treatment A, percent attachment for 
BPS 1-4 was 99.1%,96.5%,93.0% and 97.2% respectively. These 
results were not significantly different. In treatment D, percent 
attachment for BPS 1-4 was 56.3%, 1.0%, 1.9% and 9.0%. Anal-
ysis of variance showed significantly greater percent attachment 
(p < .01) with BPS #1 compared to BPS #2-4 in Treatment D. 
Effect of Incubation Time on Induction of BMZ Separation 
in Treatments A and D 
To determine if BMZ separation in treatments A and D 
varied with incubation time, the percent of sections separated 
and percent of BMZ separation were calculated for all sections 
incubated 60, 90, or 120 min. The results ru'e summarized in 
Table V. In treatment A, the percent of sections separated at 
incubation times 60, 90, and 120 min was 62%, 80% and 62% 
respectively. In treatment A, percent of BMZ separation for 
sections incubated 60, 90 and 120 min was 4.1%,7.8% and 6.4% 
respectively. These results showed no significant difference in 
BMZ separation due to incubation time in treatment A. In 
treatment D, percent of sections separated and percent of BMZ 
separation were 19% and 1.5% at 60 min; 32% and 1.9% at 90 
min and 4% and 0.7% at 120 min. Analysis of' these results 
showed no significant differences in BMZ separation due to 
incubation time in treatment D. These results suggested that 
most of' the BMZ separation observed at 60, 90, and 120 min 
had occurred prior to 60 min incubation. 
Effect of Incubation Time on Leukocyte Attachment in 
Treatments A and D 
To determine if incubation time affected attachment, percent 
attachment, was determined for all sections incubated 60, 90, 
and 120 min in both treatments. An analysis of results (Table 
V) showed no effect of incubation time on attachment. 
Correlation Between LA and BMZ Separation in Treatments 
A -E 
A correlation co-efficient was computed between percent 
attachment and percent of sections separated and percent at-
tachment and percent of BMZ separation for treatments A-E. 
The results showed a significant correlation between attach-
ment and both percent of sections separated and percent of 
BMZ separation, r = 0.7 and 1.0, respectively, 
Activation of PBL Attached to the BMZ 
In separate experiments, skin sections were treated with each 
of the 4 BPSi or NHSi plus PBL and WHS containing 0.05% 
NBT. Examination of wet prepru'ations after 30 min incubation 
at 37°C showed that in sections treated with BPSi, greater than 
FIG 3. An example of leukocyte activation on skin sections incu-
bated for 30 min at 37°C with bullous pemphigoid serum, leukocytes 
and whole human serum containing 0,05% nitroblue tetrazoliu\1l, Leu-
kocytes at the basement membrane zone (arrow) are darkly stained 
due to intracellular precipitates of reduced nitrobiue tetrazoiium, 
90% of cells attached to the BMZ contained intracellulru' pre-
cipitates of dark blue formazan (reduced NBT) (Fig 3). Only 
rare cells randomly scattered over dermis and glass showed 
these deposits. In sections treated with NHSi, attachment was 
not seen and only occasional randomly scattered cells showed 
blue precipitates. These results show that PBL attached to the 
BMZ were activated as defined by their ability to reduce NBT. 
DISCUSSION 
Histologic studies of BP tissues have confirmed that dermal-
epidermal separation begins as small clefts (microvesicles) in 
the BMZ which enlarge and coalesce to form blisters [3,13]. 
Ultrastructural studies of "prebullous" inflamed skin have 
'shown microvesicles form following degenerative changes in 
both cellular and noncellular components of the BMZ [14,15). 
Although the cause of BMZ injury has not been proven, it is 
almost certainly due to cellulru' inflammation. In all BP blisters 
including those arising on normal-apperu'ing skin, leukocytes 
are invariably present in the upper dermis beneath the blister 
base and at the edges of lesions [3,9]. In blisters arising on 
normal-appearing skin, leukocytes, though relatively sparse, are 
concentrated near the BMZ [3]. At the edges of these lesions a 
"monolayer" of leukocytes just beneath the BMZ has been 
reported . Beneath the blister base, the "monolayer" of leuko-
cytes frequently becomes a "polylayer" 2-3 cells thick. 
Studies of inflamed prebullous skin have shown a progressive 
accumulation of leukocytes in the upper dermis and beneath 
the BMZ prior to blister formation. Coincident with dermal-
epidermal separation large numbers of degranulating leuko-
cytes are present either on or in proximity to the BMZ [16]. 
Ultrastructural and histochemical studies of these lesions have 
shown that degranulating leukocytes are in direct contact with 
the BMZ at the time injury occurs and release lysosomal 
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enzymes on the lamina lucid a prior to BMZ separation 
[14,17]. 
In recent yeaTs, considerable evidence has been presented 
suggesting a role fo], immune complexes and C in the pathogen-
esis of cellular inflammation and BMZ injury. This evidence 
includes: (1) the finding of immune reactants (IgG and C 
components) at the BMZ in lesional and perilesional skin 
[18-22]; (2) IgG C-activating anti-BMZ antibodies in sera 
[7,8,23,26]; (3) evidence for C-activation and generation offunc-
tiona! C mediators in blister fluids [27-29]; (4) recent evidence 
confirming that immune reactants in BP skin are C-activating 
immune complexes and (5) evidence that functional immune 
complex activity at the BMZ is greater in lesional than normal-
appeal"ing BP skin [30]. 
In this study, additional evidence that immune complexes, 
leukocytes and C are important in BMZ injury and dermal-
epidermal separation has been obtained. When cryostat sec-
tions of fresh-frozen normal human skin were incubated with 
BPS containing C-binding anti-BMZ antibodies, viable PBL 
and WHS, leukocytes attached to and were activated at the 
BMZ and BMZ sepa.ration histologically similar to the micro-
vesicles observed in evolving lesions developed. 
A requirement for C-binding anti-BMZ antibodies in sepa-
ration was supported by the finding that significant separation 
occurred only in sections treated with BPS, PBL, and WHS. 
Furthermore, all 4 BPS caused an equivalent amount of sepa-
ration. Skin treated with either of 4 NHS, PBL and WHS was 
not significantly changed. A requirement for serum C was 
supported by the findings that significantly greater separation 
occuned in skin treated with BPS, PBL, and WHS than in 
sections treated with PBS, PBL, and heat-inactivated WHS. 
In this model, BMZ separation was absolutely dependent on 
viable PBL. In skin not treated with PBL or treated with killed 
(freeze-thawed) cells, no separation was observed. The require-
ment for viable leukocytes, the correlation observed between 
PBL attachment and BMZ separation, and the finding that 
attached cells were activated provide strong support that leu-
kocytes caused separation. Evidence that separation was not 
due to trauma or anti-BMZ antibody and C alone was provided 
by the findings that no separation occurred in any sections 
when viable PBL were omitted. 
A role for C-binding anti-BMZ antibodies, serum C and PBL 
in attachment and BMZ separation is further supported by 
previous studies of the model in which it was shown that 
attachment required BPS or IgG fractions of BPS containing 
C-binding anti-BMZ antibodies [7,8]. In those studies NHS, 
disease control sera or BPS not containing C-binding anti-BMZ 
antibodies did not cause attachment. BPS containing non-C-
binding anti-BMZ antibodies were also ineffective in causing 
attachment under the conditions employed. A role for C in 
those studies was suggested by the findings that attachment 
required WHS and that titers of BPS mediating attachment 
correlated highly with C-binding anti-BMZ titers. FUJ'thermore, 
an absolute requirement for C was confirmed by the findings 
that attachment occurred in the presence of WHS and C2-
deficient serum reconstituted with purified C2 but not with 
heat-inactivated serum, C2-deficient serum alone or serum de-
complemented with aggregated gammaglobulin or zymosan. In 
those studies the mechanism of leukocyte attachment was 
shown to involve the C-dependent directed migration (chemo-
taxis) of PBL to the BMZ. 
An unexpected finding in this study was that some degree of 
attachment and BMZ separation was observed in skin treated 
with BPS, PBL and heat inactivated WHS (Treatment D). 
This result would suggest that C-activation might not be an 
absolute requirement for attachment and separation. It is con-
ceivable that anti-BMZ antibody alone could cause attachment 
and activation of leukocytes. Leukocytes are known to have 
membrane receptors for the Fc portion of complexed IgG and 
become activated when exposed to IgG-coated particles in the 
absence of C [31-35]. FUlthermore, leukocytes exposed to IgG 
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complexes in the absence of C may produce chemotactic factors 
that attract additional cells to sites of immune complex depo-
sition [36]. In the model described here, a few leukocytes should 
encounter BMZ immune complexes by random chance alone. 
These random encounters might result in activation of cells and 
the production of leukocyte-derived chemotactic factors that 
could then recruit additional cells to the BMZ. Although such 
a mechanism may account for our findings we do not feel that 
a role for C in treatment D can be absolutely excluded. Al-
though C was not intentionally added it could have been 
introduced inadvertantly on skin sections, on PBL or could 
have been synthesized by PBL in the chambers [37,38]. An 
additional unexplained result in treatment D was the finding 
that BPS #1 caused significantly greater attachment (but not 
greater separation) than BPS #2, 3, or 4. The serum was 
thoroughly heat-inactivated to remove C and as shown in Table 
1, did not differ significantly from the other BPS in titers of C-
binding anti-BMZ antibodies. Further studies to examine this 
finding are in progress. 
The in vitro model described here demonstrates many of the 
functional interactions between skin, leukocytes, anti-BMZ 
antibodies and C that have been proposed in BP. In the model, 
immune complexes are formed at the BMZ, the C system is 
activated, PBL are recruited, activated and cause BMZ sepa-
ration. Presumably, BMZ separation occurs as a result of tissue 
destructive mediators released f!'Om activated PBL. The PBL 
used here consisted primarily of neutrophils which are known 
to release proteinases such as collagenase, cathepsin G and 
elastase as well as reactive oxygen intermediates such as super-
oxide anion, hydrogen peroxide and oxygen radicals when stim-
ulated by immune complexes [39,40]. Presently, studies are 
being performed to determine which of these tissue destructive 
mediators is important in the in vitro model and to determine 
the ultrastructural features of damage. 
Although there are many immunologic and histologic simi-
larities between the in vitro model and BP lesions, there is a 
notable difference. In lesions, the most abundant granulocyte is 
the eosinophil, in the model it is the neutrophil [39,1,7]. The 
abundance of eosinophils in lesions, their proximity to the BMZ 
and morphologic and histochemical evidence for activation and 
release of lysosomal enzymes at the BMZ suggests the cell may 
contribute to BMZ injury in vivo [3,9,16,17]. In the model, the 
neutrophil is probably the cell most responsible for BMZ sep-
aration since it is the major cell in PBL suspensions and the 
most abundant cell attached to the BMZ. Although eosinophils 
were not used in these studies, it is likely they would perform 
similar to neutrophils. Like neutrophils eosinophils are capable 
of dil'ect migration in response to C-derived chemotactic factors 
and immune adherence to antibody and C-coated surfaces 
[41,42]. Fwthermore, the eosinophil contains a variety of lyso-
somal enzymes and is able to produce reactive oxygen inter-
mediates that could lead to tissue injury [43,44]' In preliminary 
studies using purified suspensions of human eosinophils we 
have shown they will migrate and attach to the BMZ of skin 
sections and studies are in progress to determine if they can 
cause BMZ damage in vitro. 
In conclusion, an in vitro model of immune complex-me-
diated BMZ separation has been described. Optin1al damage 
was shown to require C-binding pemphigoid antibodies, viable 
PBL and serum C. Evidence for leukocyte-mediated damage 
was supported by the findings that there was an absolute 
requirement for viable leukocytes in causing damage, a high 
con-elation between leukocyte attachment and separation and 
leukocytes attached to the BMZ were activated. Preliminary 
evidence suggesting that C might not be an essential factor in 
attachment and damage with some BPS was obtained. This 
study provides additional in vitro evidence supporting a func-
tional role for immune complex-mediated inflammation in the 
pathogenesis of BP blisters. 
The authors wish to exp ress appreciation to Mrs. Virginia S. Moore 
for p,reparation of this manuscript. 
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